Literature DB >> 22562244

The Trop-2 signalling network in cancer growth.

E Guerra1, M Trerotola, A L Aloisi, R Tripaldi, G Vacca, R La Sorda, R Lattanzio, M Piantelli, S Alberti.   

Abstract

Our findings show that upregulation of a wild-type Trop-2 has a key controlling role in human cancer growth, and that tumour development is quantitatively driven by Trop-2 expression levels. However, little is known about the regulation of expression of the TROP2 gene. Hence, we investigated the TROP2 transcription control network. TROP2 expression was shown to depend on a highly interconnected web of transcription factors: TP63/TP53L, ERG, GRHL1/Get-1 (grainyhead-like epithelial transactivator), HNF1A/TCF-1 (T-cell factor), SPI1/PU.1, WT (Wilms' tumour)1, GLIS2, AIRE (autoimmune regulator), FOXM1 (forkhead box M1) and FOXP3, with HNF4A as the major network hub. TROP2 upregulation was shown to subsequently drive the expression and activation of CREB1 (cyclic AMP-responsive-element binding protein), Jun, NF-κB, Rb, STAT1 and STAT3 through induction of the cyclin D1 and ERK (extracellular signal regulated kinase)/MEK (MAPK/ERK kinase) pathways. Growth-stimulatory signalling through NF-κB, cyclin D1 and ERK was shown to require an intact Trop-2 cytoplasmic tail. Network hubs and interacting partners are co-expressed with Trop-2 in primary human tumours, supporting a role of this signalling network in cancer growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562244     DOI: 10.1038/onc.2012.151

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.

Authors:  Xi Wang; Min Long; Ke Dong; Fang Lin; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Hui-Zhong Zhang
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

Review 2.  Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

Authors:  Anton M Jetten
Journal:  Trends Cancer       Date:  2019-08-20

Review 3.  Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2015-06-24       Impact factor: 5.150

4.  Overexpression of EpCAM and Trop2 in pituitary adenomas.

Authors:  Xin Chen; Bo Pang; Yu Liang; Shang-Chen Xu; Tao Xin; Hai-Tao Fan; Yan-Bing Yu; Qi Pang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  Trop2 gene: a novel target for cervical cancer treatment.

Authors:  Xiaoqi Liu; Siqi Li; Faping Yi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553

6.  Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA.

Authors:  Roberto Plebani; Gavin R Oliver; Marco Trerotola; Emanuela Guerra; Pamela Cantanelli; Luana Apicella; Andrew Emerson; Alessandro Albiero; Paul D Harkin; Richard D Kennedy; Saverio Alberti
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  Prognostic value of TROP2 in human nasopharyngeal carcinoma.

Authors:  Guo-Fang Guan; De-Jun Zhang; Lian-Ji Wen; Duo-Jiao Yu; Yan Zhao; Lin Zhu; Ying-Yuan Guo; Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  A multi-layer inference approach to reconstruct condition-specific genes and their regulation.

Authors:  Ming Wu; Li Liu; Hussein Hijazi; Christina Chan
Journal:  Bioinformatics       Date:  2013-04-22       Impact factor: 6.937

9.  A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

Authors:  Gentry T King; Keith D Eaton; Brandon R Beagle; Christopher J Zopf; Gilbert Y Wong; Heike I Krupka; Steven Y Hua; Wells A Messersmith; Anthony B El-Khoueiry
Journal:  Invest New Drugs       Date:  2018-01-15       Impact factor: 3.850

Review 10.  Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.

Authors:  K M Fenn; K Kalinsky
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.